mTOR Inhibitors Global Market Report 2024

The mtor inhibitors market has grown strongly in recent years. It will grow from $7.11 billion in 2023 to $7.52 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The expansion observed in the historical period can be attributed to several factors. These include advancements in oncology treatments, particularly in the management of renal cell carcinoma, developments in transplantation medicine, ongoing clinical research, and progress in drug development, as well as the application of immunosuppressive treatments across various medical contexts.

The mtor inhibitors market is expected to see strong growth in the next few years. It will grow to $9.3 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. Anticipated growth in the forecast period can be linked to several factors, including the broadening of oncology applications, advancements in precision medicine, a rise in transplantation cases, the management of chronic diseases, and the increasing population of older adults.

The escalating prevalence of kidney diseases is anticipated to significantly drive the expansion of the mTOR inhibitors market. These diseases gradually deteriorate kidney function, prompting the use of mTOR inhibitors such as sirolimus and everolimus for treatment. Immunosuppressive therapies employing mTOR inhibitors play a crucial role in preventing rejection following renal transplantation. Reports from the International Society of Nephrology in April 2022 indicated that over 800 million individuals globally, accounting for 10% of the population, suffer from chronic renal disease, while approximately 843.6 million people face stages 1 to 5 of kidney diseases. This growing prevalence is a substantial driver behind the burgeoning mTOR inhibitors market.

The upsurge in cancer diagnoses worldwide is poised to significantly fuel the expansion of the mTOR inhibitor market. Dysregulation of the mTOR pathway, a key regulator of cell growth and survival, is often observed in various cancers, contributing to their progression. Projections from the World Cancer Research Fund International in February 2023 indicate an anticipated rise to almost 29 million global cancer cases by 2040. This surge in cancer diagnoses globally underscores the crucial role of mTOR inhibitors in addressing these conditions, consequently propelling the market's growth.

The burgeoning aging population is projected to substantially drive the growth of the mTOR inhibitor market. The rise in median age due to declining fertility rates and increased life expectancy has led to a higher prevalence of age-related ailments that can be targeted by mTOR inhibitors, such as cancer and Alzheimer's disease. Forecasts from the ARC Centre of Excellence in Population Ageing Research indicate a substantial increase in Australia's population aged 65 and above by 2041, rising by 54% compared to 2021. This demographic shift significantly contributes to the expanding market for mTOR inhibitors.

Collaboration and partnerships are emerging as prominent trends in the mTOR inhibitors market. Companies are forming alliances to gain traction in this sector. For example, in October 2022, Mirati Therapeutics, Inc. collaborated with Aadi Bioscience, Inc. to leverage a combination of drugs for patients with specific cancers. Another significant partnership occurred between Cambrian Biopharma and Novartis in February 2022, focusing on innovative compounds targeting the mTOR pathway. These collaborations aim to advance precision therapies and drive advancements in cancer treatments.

Major players in the mTOR inhibitor market are prioritizing product innovation, exemplified by the introduction of FYARRO. FYARRO, developed by Aadi Bioscience, Inc., is a prescription medicine for treating malignant perivascular epithelioid cell tumors (PEComa) in adults. Approved in November 2021, FYARRO is the first approved therapy for this rare and aggressive sarcoma, marking a significant advancement in addressing this condition.

Major companies operating in the mtor inhibitors market report are Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, LC Laboratories, Exelixis Inc., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Accord Healthcare Inc., Par Pharmaceutical, AbbVie Inc., GlaxoSmithKline plc, Biocon Limited, Alkem Laboratories Ltd., Gland Pharma Ltd., Apotex Inc., Glenmark Pharmaceuticals Ltd., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck & Co. Inc., AmpliPhi Biosciences Corporation, Melinta Therapeutics Inc., Aduro Biotech Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation.

North America was the largest region in the mTOR inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mtor inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mtor inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key products within the mTOR inhibitors category include Rapamune, Afinitor, Torise, Zortress, among others. Rapamune is a medication designed to prevent the rejection of organ and bone marrow transplants. Specifically, Rapamune, as an mTOR inhibitor, is prescribed for patients with lymphangioleiomyomatosis. These inhibitors find application across various medical domains including oncology, immunosuppression, and organ transplantation. They are administered through oral and intravenous routes and serve multiple purposes such as tumor treatment, kidney transplants, and more. Distribution channels for mTOR inhibitors encompass hospital pharmacies, retail pharmacies, and online pharmacies.

The mTOR inhibitors market research report provides mTOR inhibitors market statistics, including the mTOR inhibitors industry's global market size, regional shares, competitors with an mTOR inhibitors market share, detailed mTOR inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the mTOR inhibitors industry. This mTOR inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mTOR inhibitor market consists of sales of branded and generic mTOR inhibitor tablets and capsules. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.